or
forgot password

Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT


N/A
18 Years
N/A
Not Enrolling
Both
Non-Hodgkin's Lymphoma

Thank you

Trial Information

Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT


Inclusion Criteria:



- Patients must have a diagnosis of CD20-positive B-cell NHL and a staging 18F FDG
PET/CT prior to the 64Cu-DOTA-Rituximab PET/CT

- Patients must understand and voluntarily sign an Informed Consent form after the
contents have been fully explained to them

- Patients must be scheduled for rituximab-based therapy

- Patients must be older than 18-year-old

Exclusion Criteria:

- Patients who cannot complete a PET/CT scan

- Pregnant women

- Patients participating in other research protocols will be excluded from this study

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

Change in pre and post treatment SUV max value on the 64CU-DOTA-Rituximab PET/CT and 18F FDG PET/CT

Outcome Description:

Pre- and post-treatment tumor SUVmax value on the 64Cu-DOTA-Rituximab PET/CT and 18F FDG PET/CT, and resulting EORTC-based classification of patients as responding or not responding to treatment.

Outcome Time Frame:

baseline and 6 weeks

Safety Issue:

Yes

Principal Investigator

Sanjiv Gambhir, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

United States: Food and Drug Administration

Study ID:

LYMIMG0002

NCT ID:

NCT01598558

Start Date:

January 2012

Completion Date:

December 2015

Related Keywords:

  • Non-Hodgkin's Lymphoma
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location
Stanford University Cancer Institute Stanford, California  94305